Shaoxing Hantai Pharmaceutical expands global API supply network

Shaoxing Hantai Pharmaceutical is widening its international footprint with a larger portfolio of human APIs, excipients, veterinary medicines and related chemical products. The China-based supplier says its production network, overseas offices and catalog breadth are designed to help pharmaceutical buyers source ingredients across more than 60 countries and regions.

Why it matters: - Shaoxing Hantai Pharmaceutical is positioning itself as a broader sourcing partner for drugmakers, distributors and animal-health companies. - The company’s mix of human APIs, excipients and veterinary products addresses multiple parts of the pharmaceutical supply chain. - Buyers in regulated markets need suppliers that can provide product documentation, manufacturing details and export support.

What happened: - Shaoxing Hantai Pharmaceutical Co., Ltd. said it is strengthening its role in the pharmaceutical supply chain through a wider portfolio of active pharmaceutical ingredients, pharmaceutical excipients, veterinary medicines and related chemical products. - The company was established in April 2010 and is headquartered in Xinchang County, Shaoxing, Zhejiang Province, China. - Hantai Pharma reports two production bases, an operations center in Hangzhou and five overseas offices. - The company says it serves customers in more than 60 countries and regions.

The details: - The company’s product range includes pharmaceutical raw materials, chemical intermediates, pharmaceutical packaging materials, fine chemicals, agricultural and veterinary products, plant extracts and other health-related ingredients. - Human API products listed in the catalog include Amoxicillin, Azithromycin, Cephalexin, Paracetamol, Prednisolone and Ursodeoxycholic acid. - The catalog also includes selected newer molecules and specialized ingredients. - Pharmaceutical excipient offerings are listed as a separate category, giving customers a single supplier contact for related sourcing needs. - Veterinary-related products listed include Amitraz, Abamectin, Albendazole and Afoxolaner. - Hantai Pharma says its annual API production exceeds 300 tons. - The company offers an online product catalog and inquiry process for prospective customers. - The company’s website is more information.

Between the lines: - Broader product coverage can make supplier qualification easier for buyers that source multiple ingredient types from one vendor. - In pharmaceutical purchasing, catalogue breadth alone does not replace product-specific review of specifications, quality records and regulatory fit. - Hantai’s emphasis on international business suggests the company is competing on export readiness as much as on product range.

What's next: - Buyers will still need to confirm the grade, manufacturing source, documentation and commercial terms for each ingredient before placing orders. - Veterinary and excipient products will require separate technical and regulatory review depending on the destination market. - The company’s growth will depend on maintaining product quality and meeting documentation expectations across different regions.

The bottom line: - Hantai is betting that a wider portfolio and export-oriented operations will help it win more global pharmaceutical sourcing business.